A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04735393 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

757

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Placebo Comparator
DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Placebo Comparator

Sponsor

Aldeyra Therapeutics, Inc.